The scientist’s investigation covers issues in Tuberculosis, Mycobacterium tuberculosis, Immunology, Pharmacology and Pharmacokinetics. The concepts of her Tuberculosis study are interwoven with issues in Antibiotics, Lung and Linezolid. Her Antibiotics research focuses on Lesion and how it connects with Moxifloxacin and Rifampicin.
The Mycobacterium tuberculosis study combines topics in areas such as Drug development, Drug resistance, Microbiology, In vivo and Drug discovery. Her studies examine the connections between Immunology and genetics, as well as such issues in Latent tuberculosis, with regards to Clinical disease and Lesion progression. Her Pharmacology research incorporates themes from Plasmodium falciparum, Spiroindolone and Plasmodium berghei.
Véronique Dartois mainly investigates Tuberculosis, Mycobacterium tuberculosis, Pharmacology, Microbiology and Immunology. The various areas that Véronique Dartois examines in her Tuberculosis study include Antibiotics and Drug resistance. Her Mycobacterium tuberculosis study also includes fields such as
Within one scientific family, Véronique Dartois focuses on topics pertaining to Plasmodium berghei under Pharmacology, and may sometimes address concerns connected to Plasmodium falciparum and Spiroindolone. Her Microbiology study incorporates themes from Mycobacterium abscessus, Mycobacterium, Bacteria and Mutant. Immunology is frequently linked to Latent tuberculosis in her study.
Her primary scientific interests are in Tuberculosis, Mycobacterium tuberculosis, Pharmacology, Microbiology and Pharmacokinetics. Her Tuberculosis research integrates issues from Efficacy, Antibiotics and Potency. Her research integrates issues of Pharmacophore, Computational biology, Drug resistance and Cephalosporin in her study of Mycobacterium tuberculosis.
Her study looks at the relationship between Drug resistance and fields such as Gene, as well as how they intersect with chemical problems. She interconnects Antitubercular Agent, Laser capture microdissection and In vivo in the investigation of issues within Pharmacology. Her Pharmacokinetics research is multidisciplinary, relying on both Metabolite, Gastroenterology and Delamanid.
Her scientific interests lie mostly in Tuberculosis, Microbiology, Mycobacterium abscessus, Pharmacology and Pyrazinamide. Her study in Tuberculosis is interdisciplinary in nature, drawing from both Potency, Frameshift mutation, Phase variation, Drug tolerance and Gene. Her Microbiology research is multidisciplinary, incorporating perspectives in Fatty acid, Mycobacterium tuberculosis, Innate immune system, Reversion and Virulence.
Her Mycobacterium tuberculosis research is multidisciplinary, incorporating elements of NADPH oxidase, Xenophagy, Immune system, Intracellular parasite and Beta oxidation. Her research in Pharmacology intersects with topics in Statin and Adjunctive treatment. Her Pyrazinamide study combines topics from a wide range of disciplines, such as Lesion, Gastroenterology, Regimen, Internal medicine and Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
Clifton E. Barry;Helena I. Boshoff;Véronique Dartois;Thomas Dick.
Nature Reviews Microbiology (2009)
Spiroindolones, a Potent Compound Class for the Treatment of Malaria
Matthias Rottmann;Matthias Rottmann;Case McNamara;Bryan K.S. Yeung;Marcus C.S. Lee.
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
Myungsun Lee;Jongseok Lee;Matthew W. Carroll;Hongjo Choi.
The New England Journal of Medicine (2012)
Spirotetrahydro β-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.
Bryan K S Yeung;Bin Zou;Matthias Rottmann;Suresh B Lakshminarayana.
Journal of Medicinal Chemistry (2010)
The association between sterilizing activity and drug distribution into tuberculosis lesions
Brendan Prideaux;Laura E. Via;Matthew D. Zimmerman;Seokyong Eum.
Nature Medicine (2015)
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.
Nature Reviews Microbiology (2014)
An adenosine nucleoside inhibitor of dengue virus
Zheng Yin;Zheng Yin;Yen Liang Chen;Wouter Schul;Qing Yin Wang.
Proceedings of the National Academy of Sciences of the United States of America (2009)
Tryptophan Biosynthesis Protects Mycobacteria from CD4 T-Cell-Mediated Killing
Yanjia J. Zhang;Manchi C. Reddy;Thomas R. Ioerger;Alissa C. Rothchild.
ClpP of Bacillus subtilis is required for competence development, motility, degradative enzyme synthesis, growth at high temperature and sporulation.
Tarek Msadek;Véronique Dartois;Frank Kunst;Marie‐Laure Herbaud.
Molecular Microbiology (1998)
A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy
Kevin Pethe;Patricia C. Sequeira;Sanjay Agarwalla;Kyu Rhee.
Nature Communications (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: